GLOBAL HEALTH | GLOBAL PARTNERSHIPS | GLOBAL IMPACT

Research

Photo for CHARM

CHARM

Official Title

Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity

Status

Completed

Overview

To determine the effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall Programme.

Study Design

Randomized, double-blind, parallel group design.

Primary Endpoint

The primary outcome was all-cause death. The outcomes in the three component trials were: cardiovascular death or hospitalization for worsening heart failure; cardiovascular death, admission to hospital for CHF, or non-fatal myocardial infarction; cardiovascular death, admission to hospital for CHF, non-fatal myocardial infarction, or non-fatal stroke; cardiovascular death, admission to hospital for CHF, non-fatal myocardial infarction, non-fatal stroke, or coronary revascularisation; death (any cause) or admission to hospital for CHF; and development of new diabetes. All outcome events were adjudicated.

Number of Patients

7601

Number of Sites

618

Number of Countries

24

Study Period

1999–2000

Principal Investigator

Salim Yusuf

Program Manager

Not Applicable

Research Coordinator

Not Applicable

Key Publications

  • Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S; CHARM Investigators and Committees.Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003 Sep 6;362(9386):767-71.
  • Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003 Sep 6; 362(9386):777-81.